Eterna Therapeutics expands license from Factor Bioscience, gains know-how and multi-tier sublicense rights

Ernexa Therapeutics Inc.

Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.
CEO Matthew Angel is co-founder, President, CEO and director of Factor's parent company, creating a related-party transaction.
Licensor's termination rights are reduced; technology transfer to Eterna is now included subject to use restrictions.
Original agreement was from Feb 20, 2023, amended July 12, 2023; this restatement replaces it entirely.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ernexa Therapeutics Inc. entered into Exclusive Amended and Restated License Agreement with Factor Bioscience Limited (effective 2023-11-14).

Action: entry
Agreement: license
Counterparty: Factor Bioscience Limited
Effective: 2023-11-14

Exact text from the filing

On November 14 , 2023, Eterna Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Exclusive Amended and Restated License Agreement (the “A&R Agreement”) with Factor Bioscience Limited (“Factor”) to replace in its entirety the Exclusive License Agreement dated February 20, 2023

View on SEC.gov

Browse all material agreements →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-053659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.